Physician profile
Thomas Lambert
NPI 1780104273
$9,614.90
in general payments reported to CMS, 2019-2025
24 companies · $803 in 2025
The $803 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $405 · 2021: $1,277 · 2022: $2,873 · 2023: $656 · 2024: $1,645 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Travel and Lodging: $557 · Entertainment: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.25 |
| Travel and Lodging | $557.01 |
| Entertainment | $130.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $4,183.37 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $2,053.81 | 2019-2025 | Hydrus Microstent, Voyager Dslt, Clareon Panoptix Pro |
| Coopervision INC. | $584.65 | 2019-2025 | Misight Contact Lens |
| Abbvie INC. | $355.16 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $335.60 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $252.56 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $242.02 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $148.41 | 2022 | |
| Dompe US, INC. | $132.86 | 2024-2025 | Oxervate |
| Optos, INC. | $130.17 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $121.95 | 2021 | |
| Amgen INC. | $120.22 | 2024 | Tepezza |
| Allergan, INC. | $117.87 | 2021 | |
| Bausch & Lomb Americas INC. | $115.68 | 2022 | |
| Oyster Point Pharma, INC. | $112.33 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $112.07 | 2019 | |
| Notal Vision, INC. | $103.59 | 2022 | |
| Lensar, INC. | $78.26 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $70.11 | 2023 | Lipiflow System Activator (Disposable) |
| Sun Pharmaceutical Industries INC. | $63.71 | 2021 | |
| Astellas Pharma US INC | $58.81 | 2024 | Izervay |
| Glaukos Corporation | $51.28 | 2021 | |
| Abb Con-Cise Optical Group LLC | $42.73 | 2019 | |
| Biotissue Holdings INC. | $27.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.